Myasthenia Gravis (MG) is an autoimmune neuromuscular disorder characterized by muscle weakness, most commonly due to autoantibody-mediated loss of functional acetylcholine receptors (AChR) in the neuromuscular junction. AChR binding autoantibodies are diagnostic of MG, and are found in 85-90% of MG patients. AChR modulating antibodies cross-link AChR molecules on cell surface, promoting internalization, and decreasing AChR surface density. The AChR binding and modulating antibody assays have similar sensitivities, but performing them together increases sensitivity of antibody detection by approximately 5%.
Sample Type
Serum
Collect
Gold or red top
Amount to Collect
2 mL blood
Preferred Volume
1 mL serum
Minimum Volume
0.5 mL serum
Stability (from collection to initiation)
Room temperature: 14 days
Refrigerated: 14 days
Frozen: 30 days
Room temperature: 14 days
Refrigerated: 14 days
Frozen: 30 days
Units
% binding inhibition
Reference Interval
< 32%
Additional Information
Myasthenia Gravis (MG) is an autoimmune neuromuscular disorder characterized by muscle weakness, most commonly due to autoantibody-mediated loss of functional acetylcholine receptors (AChR) in the neuromuscular junction. AChR binding autoantibodies are diagnostic of MG, and are found in 85-90% of MG patients. AChR modulating antibodies cross-link AChR molecules on cell surface, promoting internalization, and decreasing AChR surface density. The AChR binding and modulating antibody assays have similar sensitivities, but performing them together increases sensitivity of antibody detection by approximately 5%.
Aliquot and freeze sample. Transport to CB frozen. Order Quest test code 26474.
Units
% binding inhibition
Reference Interval
< 32%
Stability (from collection to initiation)
Room temperature: 14 days
Refrigerated: 14 days
Frozen: 30 days
Reported
4-7 days
Additional Information
Myasthenia Gravis (MG) is an autoimmune neuromuscular disorder characterized by muscle weakness, most commonly due to autoantibody-mediated loss of functional acetylcholine receptors (AChR) in the neuromuscular junction. AChR binding autoantibodies are diagnostic of MG, and are found in 85-90% of MG patients. AChR modulating antibodies cross-link AChR molecules on cell surface, promoting internalization, and decreasing AChR surface density. The AChR binding and modulating antibody assays have similar sensitivities, but performing them together increases sensitivity of antibody detection by approximately 5%.
CPT Codes
86043
LOINC Codes
11562-6
Ordering
Available Stat
No
Performing Lab
Quest
Methodology
Radiobinding Assay
Reported
4-7 days
Additional Information
Myasthenia Gravis (MG) is an autoimmune neuromuscular disorder characterized by muscle weakness, most commonly due to autoantibody-mediated loss of functional acetylcholine receptors (AChR) in the neuromuscular junction. AChR binding autoantibodies are diagnostic of MG, and are found in 85-90% of MG patients. AChR modulating antibodies cross-link AChR molecules on cell surface, promoting internalization, and decreasing AChR surface density. The AChR binding and modulating antibody assays have similar sensitivities, but performing them together increases sensitivity of antibody detection by approximately 5%.
Collection
Sample Type
Serum
Collect
Gold or red top
Amount to Collect
2 mL blood
Preferred Volume
1 mL serum
Minimum Volume
0.5 mL serum
Stability (from collection to initiation)
Room temperature: 14 days
Refrigerated: 14 days
Frozen: 30 days
Room temperature: 14 days
Refrigerated: 14 days
Frozen: 30 days
Result Interpretation
Units
% binding inhibition
Reference Interval
< 32%
Additional Information
Myasthenia Gravis (MG) is an autoimmune neuromuscular disorder characterized by muscle weakness, most commonly due to autoantibody-mediated loss of functional acetylcholine receptors (AChR) in the neuromuscular junction. AChR binding autoantibodies are diagnostic of MG, and are found in 85-90% of MG patients. AChR modulating antibodies cross-link AChR molecules on cell surface, promoting internalization, and decreasing AChR surface density. The AChR binding and modulating antibody assays have similar sensitivities, but performing them together increases sensitivity of antibody detection by approximately 5%.
Aliquot and freeze sample. Transport to CB frozen. Order Quest test code 26474.
Units
% binding inhibition
Reference Interval
< 32%
Stability (from collection to initiation)
Room temperature: 14 days
Refrigerated: 14 days
Frozen: 30 days
Reported
4-7 days
Additional Information
Myasthenia Gravis (MG) is an autoimmune neuromuscular disorder characterized by muscle weakness, most commonly due to autoantibody-mediated loss of functional acetylcholine receptors (AChR) in the neuromuscular junction. AChR binding autoantibodies are diagnostic of MG, and are found in 85-90% of MG patients. AChR modulating antibodies cross-link AChR molecules on cell surface, promoting internalization, and decreasing AChR surface density. The AChR binding and modulating antibody assays have similar sensitivities, but performing them together increases sensitivity of antibody detection by approximately 5%.
